Dermata Therapeutics Expands At-The-Market Equity Offering Capacity

Dermata Therapeutics ( (DRMA) ) has issued an announcement.

On January 27, 2026, Dermata Therapeutics, Inc. increased the maximum aggregate amount of common stock it may issue under its at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000, following prior sales of $3,454,390 in common shares under the same agreement. The move expands the company’s capacity to raise incremental financing through ongoing share issuances, which may support its funding needs while modestly diluting existing shareholders’ ownership stakes.

The most recent analyst rating on (DRMA) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.

Spark’s Take on DRMA Stock

According to Spark, TipRanks’ AI Analyst, DRMA is a Neutral.

The score is primarily held back by pre-revenue financial performance, persistent losses, and heavy cash burn that imply ongoing financing/dilution risk. Technicals are mixed (short-term improvement but weak longer-term trend), while valuation metrics are not supportive due to negative earnings and no indicated dividend yield. Corporate events provide some funding relief but introduce uncertainty from a major strategic pivot.

To see Spark’s full report on DRMA stock, click here.

More about Dermata Therapeutics

Dermata Therapeutics, Inc. is a biotechnology company whose common stock trades publicly, using equity offerings as a source of capital to fund its operations and development activities.

Average Trading Volume: 1,410,607

Technical Sentiment Signal: Sell

Current Market Cap: $8.73M

See more insights into DRMA stock on TipRanks’ Stock Analysis page.